Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...
Company
Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs
hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...
Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development
China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...
Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received...
Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...
Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System
US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...
Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has received clearance from the National Medical...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...
AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s (AZ, NASDAQ: AZN) Truqap (capivasertib) for...
Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone
Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...
Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...
BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...
Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment
German pharmaceutical giant Bayer AG (ETR: BAYN) has completed a 70,000-square-foot expansion at its Myerstown,...
Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China
The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...
Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102
Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into...
Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes
U.S. pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has announced positive top-line results from...
3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China
China-based 3SBio Inc. (HKG: 1530) has announced the receipt of Breakthrough Therapy Designation (BTD) from...
NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development
NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed...
La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone
Switzerland-based Clinique La Prairie Holistic Health SA has received approval for its functional nutrient product...